Avacta still a ways off..My correction.. Avacta is working on two tests.. one is lab based, and the one with Cytiva is still in development. Listening to the Webinar on June 17th Claus and Avacta rep made it clear they are still a ways off.. ready for next Pandemic.
Lab test in development with Adeptrix.
Following generation of Affimer reagents, the next stage is to implement them into a test form. Currently for COVID-19, we are working with Cytiva to develop POC and consumer LFA diagnostics, to detect the SARS-CoV-2 virus spike protein from saliva samples, which are less intrusive for patients than nasal and throat swabs. In addition, with Adeptrix we’re developing a laboratory-based test to provide an alternative to PCR lab testing, offering greater testing capacity to meet the high demand for accurate, high performance diagnostics.
The Adeptrix high-throughput bead-assisted mass spectrometry (BAMS™) test format runs on the already installed base of mass spectrometers in hospitals and laboratories, making use of equipment that is already present but not yet being utilised for COVID-19 testing. On June 9th 2020, we announced this test has reached prototype stage and can detect the SARS-COV-2 spike protein in model samples in the concentration range appropriate for a clinical diagnostic test. On 24th June we announced positive initial data from the first Affimer-based rapid test strips.